CNAO

What CNAO does

CNAO (Fondazione Centro Nazionale di Adroterapia Oncologica) is an Italian non-profit foundation that operates the country's only synchrotron-based hadrontherapy center, located in Pavia approximately 30 minutes from Milan. Founded in 2001 by the Italian Ministry of Health following a 1991 scientific proposal by physicists Ugo Amaldi and Giampiero Tosi, the center treats oncological patients with tumors that are radio-resistant to conventional X-ray radiotherapy or surgically inoperable, including brain, head and neck, chest, abdominal, pelvic, and pediatric solid tumors. The patient base is built primarily through physician referrals from oncologists across Italy, with secondary access via direct clinical documentation submission for both domestic patients (covered by SSN) and international patients (via EU mobility, bilateral agreements, or private pay).

The foundation's core technology is an 80-meter circumference, 25-meter diameter synchrotron housed in a 1,600 square meter bunker with 2-6 meter reinforced concrete shielding, accelerating protons to 250 MeV and carbon ions to 4,800 MeV. This dual-particle capability makes CNAO one of only six facilities worldwide able to deliver both proton and carbon ion therapy. An active scanning system directs the beam along tumor contours using two scanning magnets with 200-micrometer precision, supported by infrared-based continuous patient motion tracking. The synchrotron was engineered through collaboration with INFN, CERN, GSI (Germany), and LPSC (France). Service modules include a structured therapeutic pathway, a dedicated Physician Area with chat-enabled case submission, and an active clinical research program in radiobiology and translational oncology. The center has treated over 6,000 oncological patients since becoming operational in 2011, with planned capacity of approximately 700 patients per year.

Revenue derives from two streams: reimbursement from the Italian National Health Service (SSN) under the Livelli Essenziali di Assistenza (LEA) framework, with hadrontherapy recognized since 2014 and formally included in LEA in 2017; and private pay/self-pay for non-LEA indications. As a non-profit foundation, CNAO does not have equity shareholders; its €135M construction and €37.1M clinical validation phases were grant-funded by the Italian Ministry of Health, and ongoing funding flows through SSN reimbursement, research grants, and donations (including the 5x1000 Italian tax designation program). An Expansion Project adding a second building with Hitachi proton therapy equipment and TAE Life Sciences BNCT technology is planned for 2026 inauguration.

Name

CNAO

Legal name

Fondazione Centro Nazionale di Adroterapia Oncologica

Website

https://fondazionecnao.it

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

CNAO is an Italian non-profit foundation operating the country's only synchrotron-based hadrontherapy center, treating radio-resistant and inoperable oncological tumors with protons and carbon ions, reimbursed primarily by the Italian National Health Service.

Ownership category

akta.pro rank

Product category

Hadrontherapy / Oncological Radiotherapy

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Neuro-Oncology (HLAKAFAH)

Keywords

• Hadrontherapy treatment
• Proton therapy
• Carbon ion therapy
• Oncological radiotherapy
• Particle therapy center

Headquarters

HQ city

Pavia

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. National Health Service Reimbursement: Hadrontherapy is covered by the Italian National Health Service (SSN) since January 1, 2014, and has been included in the Livelli Essenziali di Assistenza (LEA) since 2017. Italian patients receive treatment at no cost for approved clinical indications.
2. Private Pay/Solvency: For indications not covered by LEA or upon specific patient request, treatment can be performed on a private pay basis.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

CNAO delivers hadrontherapy — an advanced form of radiotherapy using protons and carbon ions accelerated by a synchrotron — to treat radio-resistant and inoperable oncological tumors. The center treats patients referred by oncologists and specialists, with services covered by the Italian National Health Service (SSN) for LEA-approved indications since 2014/2017, and accepts international patients via EU mobility, bilateral agreements, and private pay. Supporting offerings include a complete therapeutic pathway from evaluation to follow-up, a dedicated physician area for case submission, and ongoing clinical, radiobiological, and translational research programs.

Product overview

CNAO (Centro Nazionale di Adroterapia Oncologica) is a National Center for Oncological Hadrontherapy offering advanced radiotherapy treatment using protons and carbon ions. The core product is Adroterapia (Hadrontherapy), a form of radiotherapy that treats inoperable or radio-resistant tumors. The technology is powered by the Sincrotrone (Synchrotron), an 80-meter particle accelerator unique in Italy. CNAO provides specialized treatment services for various tumor types including brain, head/neck, chest, abdomen, pelvis, and pediatric tumors. The center operates through integrated service modules including a Physicians Area for clinical collaboration, a Therapeutic Pathway for patient journey management, and an active Clinical Research program. An Expansion Project is underway to add proton therapy (Hitachi) and BNCT technology capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Adroterapia (Hadrontherapy) Advanced form of radiotherapy that uses protons and carbon ions instead of X-rays to treat tumors that are often inoperable or resistant to traditional radiotherapy. Delivered via a synchrotron particle accelerator, the treatment is available to adult and pediatric oncology patients with LEA-approved clinical indications (covered by the Italian NHS) and to international patients via EU mobility, bilateral agreements, or private pay.
• Pediatric Solid Tumor Hadrontherapy

Quantifiable outcome

• Over 6,000 oncological patients treated to date
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

19 partnerships are on record, tiered core and minor.

• HITRIplus (Heavy Ion Therapy Research Integration plus)coreStrategic or Co-development Partner · 31 March 2021European project coordinated by CNAO (under Director General Sandro Rossi) for integration of heavy ion therapy research. Includes networking activities, transnational access, and joint research activities. Concluded March 31, 2026.
• ULICE (Union of Light Ion Centres in Europe)coreStrategic or Co-development Partner · 1 January 2009FP7 Infrastructure project (2009-2013, 48 months) coordinated by Prof. Roberto Orecchia. Included 20 European institutes for development of light ion therapy in Europe.
• PARTNER (Particle Training Network for European Radiotherapy)minorStrategic or Co-development Partner · 1 January 2008First project year 2008. European training network for medical, technical, and medical physics personnel at hadrontherapy centers. Trained personnel from India, Singapore, and Colombia at CNAO.
• CERN (Geneva)coreStrategic or Co-development Partner · 1 January 2000Technical collaboration on PIMMS (Proton Ion Medical Machine Study) project completed in 2000. CERN technology adapted for clinical use. Ongoing technical task collaboration and support.
• INFN (Istituto Nazionale di Fisica Nucleare)coreStrategic or Co-development Partner · 1 January 1992Co-direction of accelerator technology, over 15 technical tasks, research and training collaboration. INFN was instrumental in the conceptual development of the center starting with the ATER project in 1992. Ongoing involvement in operation and research activities.
• GSI (Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany)coreStrategic or Co-development PartnerCollaboration on linac and special components, biophysics research, and dose delivery with treatment of moving organs. Contributed to the PIMMS study and technology development.
• LPSC (Laboratoire de Physique Subatomique et de Cosmologie, Grenoble, France)coreTechnology or IntegrationCollaboration on optics, betatrone, low-level RF, and control system development for the synchrotron.
• Politecnico di MilanocoreStrategic or Co-development PartnerCollaboration on patient positioning systems and radiation protection. Part of institutional participants contributing to center development and ongoing research.
• Università di PaviacoreStrategic or Co-development PartnerTechnical tasks, radiobiology research, and training programs. Founding institutional participant. Ongoing collaboration in research and clinical activities.
• Università di MilanocoreStrategic or Co-development PartnerMedical coordination and training collaboration. Founding institutional participant.
• Fondazione TERA (Novara)coreStrategic or Co-development PartnerDefinitive project, high technology specifications, and research. Created in 1992 to raise funds and personnel for center design. Provided young, qualified personnel that became core CNAO staff.
• NIRS (National Institute of Radiological Science, Chiba, Japan)minorStrategic or Co-development PartnerMedical activities collaboration, radiobiology research, and training exchange programs.
• HIT (Heidelberg University Hospital, Germany)minorStrategic or Co-development PartnerResearch collaboration activities in hadrontherapy.
• IRCCS Policlinico San Matteo (Pavia)coreStrategic or Co-development PartnerFounding member and institutional participant. Medical activities and logistics support.
• IRCCS Istituto Nazionale dei Tumori (Milano)coreStrategic or Co-development PartnerFounding member of CNAO foundation. Ongoing collaboration in medical activities.
• IRCCS Istituto Neurologico Besta (Milano)coreStrategic or Co-development PartnerFounding member of CNAO foundation.
• Istituto Europeo di Oncologia (Milano)coreStrategic or Co-development PartnerFounding member of CNAO foundation. Medical activities and authorization support.
• Ospedale Maggiore Policlinico (Milano)coreStrategic or Co-development PartnerFounding member of CNAO foundation.
• IUSS Pavia (Scuola Universitaria Superiore)coreStrategic or Co-development PartnerCollaboration on Hadron Academy doctoral program: 'Risk and complexity in high tech medical innovation'. First doctoral cycle concluded in May 2026.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• MedAustron: Austrian carbon ion + proton therapy center in Wiener Neustadt, operating since 2016. Direct peer in the European dual-particle therapy cohort along with CNAO, sharing the same PIMMS/CERN technology lineage.
• Heidelberg Ion-Beam Therapy Center (HIT): University Hospital Heidelberg facility offering both proton and carbon ion therapy in Germany. Most direct global comparable to CNAO, built with technology contributions from GSI and a sister clinical site referenced in CNAO's own partnership list.
• QST (National Institutes for Quantum Science and Technology) — Chiba: Japan's National Institute of Radiological Sciences (formerly NIRS) operates HIMAC, the original clinical carbon ion therapy center. Sister research/clinical partner of CNAO via the listed NIRS collaboration, and the pioneer that established clinical carbon ion therapy.

Regional players

• Shanghai Proton and Heavy Ion Center (SPHIC): Chinese carbon ion + proton therapy facility in Shanghai. Operates the same dual-particle modality as CNAO but in a different geography, serving primarily Chinese oncology patients with limited European overlap.
• Gunma University Heavy Ion Medical Center (GHMC): Japanese carbon ion therapy center at Gunma University. Comparable clinical offering (heavy ion radiotherapy) but geographically focused on Japan rather than competing directly with CNAO in Europe.
• iThemba LABS Proton Therapy Centre: South African proton therapy facility (and historically a neutron therapy site) operated by the South African Nuclear Energy Corporation. Provides similar particle therapy capabilities in a distinct geography from CNAO.

Others

• IBA (Ion Beam Applications): Belgian manufacturer of proton therapy systems and other particle accelerators. Enables the broader particle therapy market that CNAO competes within, rather than directly treating patients; supplies equipment to many of CNAO's global peer centers.
• Hitachi (Proton Therapy Systems): Hitachi provides proton therapy systems and is CNAO's named equipment partner for the 2026 expansion project. An enabling supplier in the particle therapy ecosystem rather than a clinical competitor, but directly relevant given the commercial partnership disclosed in the data.

Broad incumbents

• Mayo Clinic Proton Beam Therapy Program: US-based proton therapy program operating across multiple Mayo Clinic campuses. Large incumbent delivering the closest alternative modality (proton-only) within an integrated cancer care system rather than as a single-purpose specialty facility.
• MD Anderson Proton Therapy Center: Large US-based proton therapy program at MD Anderson Cancer Center. Operates within a broader oncology portfolio at one of the world's leading cancer hospitals; comparable modality but as part of a much larger institution rather than a standalone specialty center.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/fond_cnao
• Facebookfacebook.com/FondazioneCnao
• LinkedInlinkedin.com/company/fondazione-cnao
• Instagraminstagram.com/cnaofondazione

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CNAO